Iain Baird is an operating partner at Altaris and a board member of Padagis and Kindeva. Iain has a long track record of partnering with founders and management teams to build contract development and manufacturing organizations (CDMOs) and product companies including: OSO BioPharmaceuticals, CANbridge Life Sciences, Gallus Biopharmaceuticals, Brammer Bio, Mikart, Arranta Bio, Vibalogics, Genezen, Enterobiotix and Meridian Medical Technologies. Iain started his career at AstraZeneca (formerly ICI and Zeneca) where he designed and project managed the construction of pharmaceutical facilities and ran multiple production sites. Subsequently, Iain was a member of the leadership teams that established Avecia Oligonucleotides and Avecia Vaccines. Iain received a Bachelor of Engineering in Mechanical and Electrical Engineering from Robert Gordons University.

Eytan Abraham, PhD has more than 20 years of international cell and gene therapy experience and most recently served as VP, Business Head of Cell, Gene, and Nucleic Acids at National Resilience. During his time at Lonza Group AG (SIX: LONN) (“Lonza”), Eytan brought patient centric cell therapy manufacturing solutions to market through his roles as Head of CGT R&D and subsequently VP, Head of Personalized Medicine. Prior to this, Eytan held various roles in the cell and gene therapy industry including Head of Therapeutic Pipeline development at Pluristem Therapeutics Inc. (NASDAQ: PLUR). Eytan holds a Ph.D. in Neuroendocrinology and Developmental Biology from the University of Maryland as well as a post doctorate in cell therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School.

Hiroto joined Minaris in 2020 and led the business through the sale from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004), to Altaris, LLC in 2024. Prior to Minaris, Hiroto was at Takeda Pharmaceuticals Co. Ltd (NYSE: TAK) and Fujifilm Holdings Corporation (TYO: 4901) where he held various roles such as Global Head of Cell Manufacturing Strategy, and Director of Strategic Product Planning. Hiroto holds a PhD in Pharmaceutical Science from Kyoto University, an MBA from Kenichi Ohmae Graduate School and a post doctorate in Pharmaceutical Sciences from the University of Texas.

William Burckardt, CPA is the Chief Financial Officer of Minaris Regenerative Medicine. William brings over 10 years of experience in the health care and pharmaceutical industries and an extensive background in finance, accounting, audit and tax. William joined Minaris over six years ago as the Corporate Controller for the USA region and then was appointed the Chief Financial Officer, USA, in 2021.

Prior to joining Minaris, William worked at Restorix Health, a provider of wound care centers, as the Director of Accounting where he oversaw the Accounting department and supported the organization through significant growth through mergers and acquisitions. Prior to that he spent more than five years in public accounting performing audit, attestation and tax services for many clients.  During this time he received his certification as a Certified Public Accountant (CPA).

Prakash Manwani is the Chief Information Officer of Minaris Regenerative Medicine. Prakash brings over 20 years of experience in Information Technology with extensive experience in strategic planning, developing IT roadmaps, Enterprise Solution architecture, designing and executing software implementations that align with the Business goals of the Organization, with a focus on ERP and integration systems like MES, LIMS, and eQMS. He joined Minaris in 2021. 

Prior to joining Minaris, Prakash worked at Catalent Pharma for over seven years. Before that, he worked for Accenture, USA, and has held various consulting roles with MAKO Surgical Devices and PSS/World Medical, Inc. Prakash is a certified Project Manager (PMP) and holds a degree in Digital Electronics and an advanced diploma in Computer Systems Management, both from the National Institute of Information Technology, Mumbai, India. 

Darwin Richardson has more than 20 years of leadership and CDMO experience and most recently served as Chief Executive Officer of Benuvia Operations. Prior to this, Darwin served as VP Operations & General Manager for Meridian Medical Technologies, which was purchased by Altaris, LLC from Pfizer Inc. (NYSE:PFE) in 2021 and subsequently merged with Kindeva Drug Delivery in 2022. Darwin began his career at Baxter International (NYSE: BAX) before holding various leadership roles at Ajinmoto Co., Inc. (TYO: 2802), BPL Plasma, and Genzyme. Darwin holds an MBA from the University of La Verne and a B.A from California State University Fullerton.